Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Patricia A. Turney net worth and biography

Patricia Turney Biography and Net Worth

SVP of Arcutis Biotherapeutics

Ms. Turney has served as our senior vice president, operations since January 2020. She previously worked at Amgen, Inc. from 1996 to 2019 in roles of increasing responsibility, most recently as vice president, external supply, where she managed more than 50 contract manufacturing sites supporting clinical programs and commercial products. Prior Amgen roles included: executive director, medical device and direct materials; site operations head for Amgen’s Netherlands site; executive director, global facilities operations; and director, R&D strategic operations. Prior to joining Amgen, Ms Turney was a Federal Aviation Administration certified instructor, and earlier, a naval aviator in the United States Navy. She holds a Bachelor of Science in mathematics from the United States Naval Academy and a Master of Business Administration from the Anderson School, University of California, Los Angeles.

What is Patricia A. Turney's net worth?: The estimated net worth of Patricia A. Turney is at least $594,045.90 as of March 6th, 2023. Ms. Turney owns 62,862 shares of Arcutis Biotherapeutics stock worth more than $594,046 as of April 19th. This net worth evaluation does not reflect any other investments that Ms. Turney may own. Learn More about Patricia A. Turney's net worth.
How do I contact Patricia A. Turney?: The corporate mailing address for Ms. Turney and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Patricia A. Turney's contact information.
Has Patricia A. Turney been buying or selling shares of Arcutis Biotherapeutics?: Patricia A. Turney has not been actively trading shares of Arcutis Biotherapeutics within the last three months. Most recently, Patricia A. Turney sold 831 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $15.26, for a transaction totalling $12,681.06. Following the completion of the sale, the senior vice president now directly owns 62,862 shares of the company's stock, valued at $959,274.12. Learn More on Patricia A. Turney's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 80,000 shares worth more than $200,000.00. During the last year, insiders at the sold shares 5 times. They sold a total of 10,370 shares worth more than $75,737.90. The most recent insider tranaction occured on March, 4th when insider Masaru Matsuda sold 3,760 shares worth more than $41,811.20. Insiders at Arcutis Biotherapeutics own 20.7% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 3/4/2024.

Patricia A. Turney Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Sell	831	$15.26	$12,681.06	62,862
3/2/2023	Sell	1,432	$15.83	$22,668.56	45,693
2/28/2023	Sell	936	$16.17	$15,135.12	47,125
3/4/2022	Sell	993	$16.86	$16,741.98

Patricia A. Turney Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $9.45

$9.31

$10.38

50 Day Range

MA: $10.01

$6.57

$12.53

2 Week Range

Now: $9.45

$1.76

$15.21

Volume

2,917,035 shs

Average Volume

4,781,729 shs

Market Capitalization

$914.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad